Allogene Therapeutics Inc [ALLO] stock is trading at $1.27, up 3.25%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALLO shares have lost -13.61% over the last week, with a monthly amount glided 7.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on October 10, 2025, when JP Morgan downgraded its rating to a Underweight. Previously, Citizens JMP downgraded its rating to Mkt Perform on May 14, 2025. On March 14, 2025, upgrade upgraded it’s rating to Mkt Outperform but maintained its price target of $5 on the stock. Piper Sandler initiated its recommendation with a Overweight and recommended $11 as its price target on May 31, 2024. JMP Securities downgraded its rating to Mkt Perform for this stock on January 05, 2024. In a note dated January 05, 2024, Guggenheim downgraded a Neutral rating on this stock.
Allogene Therapeutics Inc [ALLO] stock has fluctuated between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.27 at the most recent close of the market. An investor can expect a potential return of 2183.46% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.59 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Allogene Therapeutics Inc’s Current Ratio is 8.92. Further, the Quick Ratio stands at 8.92, while the Cash Ratio is 1.65.
Transactions by insiders
Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Jun 10 ’25 when 36885.0 shares were sold. Director, MESSEMER DEBORAH M. completed a deal on Jun 10 ’25 to buy 36885.0 shares. Meanwhile, SVP, Finance Yoshiyama Annie sold 9601.0 shares on Apr 21 ’25.
